Effect of high-potency statins on HbA1c in patients with or without diabetes mellitus
| Autor: | Nobuhiro Ooba, Yu Yasukawa, Noriyasu Fukuoka, Shinji Hidaka, Shoutarou Tanaka, Nariyasu Yoshino, Hiroyuki Hayashi, Toshiichi Seki |
|---|---|
| Rok vydání: | 2016 |
| Předmět: |
High-potency statin
medicine.medical_specialty Statin medicine.drug_class Pharmacology (nursing) Pharmacy 030204 cardiovascular system & hematology 03 medical and health sciences 0302 clinical medicine Pharmacotherapy Internal medicine Diabetes mellitus medicine Potency Pharmacology (medical) New-user design cardiovascular diseases 030212 general & internal medicine business.industry Incidence (epidemiology) Hazard ratio nutritional and metabolic diseases Retrospective cohort study medicine.disease Hemoglobin A1c lipids (amino acids peptides and proteins) business Research Article |
| Zdroj: | Journal of Pharmaceutical Health Care and Sciences |
| ISSN: | 2055-0294 |
| DOI: | 10.1186/s40780-016-0040-0 |
| Popis: | Background The increased risk of new-onset diabetes with statin use, including high-potency statins, is well known. However, the effects of high-potency statins on HbA1c are unclear. A retrospective cohort study was conducted to examine the effect of high-potency statins on HbA1c in patients with or without diabetes. The study enrolled new statin users identified via the electronic healthcare database of the general hospital in Japan. Methods Following identification of all individuals (n = 4,672) who had been prescribed a lipid lowering drug at least once between January 1, 2010 and July 31, 2014, new statin users were selected (n = 1,136). Patients were excluded if they had been prescribed treatment with a statin within the preceding 6-month period. HbA1c levels before and during high-potency statin treatment were compared using the dependent t-test. In addition, the hazard ratio for the incidence of diabetes with high-potency statin treatment was estimated, using low-potency statins as a reference. Results In patients with diabetes (n = 153), mean HbA1c (%) levels significantly increased by 0.4 % after high-potency statin use (7.57 ± 1.58; p = 0.0002) compared to baseline (7.18 ± 1.37). Similarly, HbA1c (%) levels significantly increased from 5.78 ± 0.38 to 5.92 ± 0.45 (p |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full text from SpringerLink